Ticker > Company >

Granules India share price

Granules India Ltd.

NSE: GRANULES BSE: 532482 SECTOR: Pharmaceuticals & Drugs  180k   1k   229

533.90
+1.50 (0.28%)
NSE: 14 Nov 4:00 PM

Price Summary

Today's High

₹ 545.4

Today's Low

₹ 526.8

52 Week High

₹ 721

52 Week Low

₹ 360.1

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

12940.07 Cr.

Enterprise Value

13766.2 Cr.

No. of Shares

24.24 Cr.

P/E

34.5

P/B

4.03

Face Value

₹ 1

Div. Yield

0.28 %

Book Value (TTM)

₹  132.5

CASH

228.11 Cr.

DEBT

1054.25 Cr.

Promoter Holding

38.87 %

EPS (TTM)

₹  15.48

Sales Growth

-4.48%

ROE

15.08 %

ROCE

17.06%

Profit Growth

-12.6 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 18 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-4.48%
3 Year6.2%
5 Year12.34%

Profit Growth

1 Year-12.6%
3 Year-7.61%
5 Year21.92%

ROE%

1 Year15.08%
3 Year16.93%
5 Year21.27%

ROCE %

1 Year17.06%
3 Year17.63%
5 Year20.42%

Debt/Equity

0.3404

Price to Cash Flow

40.83

Interest Cover Ratio

9.2126

CFO/PAT (5 Yr. Avg.)

0.919016806688975

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 38.87 0.00
Jun 2024 38.87 0.00
Mar 2024 41.96 4.03
Dec 2023 41.96 4.03
Sep 2023 41.96 4.03
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has a healthy Interest coverage ratio of 9.2126.
  • The Company has been maintaining an effective average operating margins of 22.1462943856646% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 69.132 days.

 Limitations

  • The company has shown a poor profit growth of -7.61176257398398% for the Past 3 years.
  • The company has shown a poor revenue growth of 6.20089866444182% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 1009.42 984.49 940.19 851.95 567.99
Total Expenditure 800.99 737.6 750.91 674.54 465.39
Operating Profit 208.42 246.88 189.28 177.42 102.6
Other Income 1.25 0.67 3.43 1.81 2.78
Interest 17.65 19.78 19.79 17.52 14.56
Depreciation 36.01 36.16 36.41 35.85 34.75
Exceptional Items 0 0 0 0 0
Profit Before Tax 156.01 191.61 136.51 125.86 56.07
Tax 39.86 48.91 39.3 32.08 14.68
Profit After Tax 116.16 142.71 97.22 93.78 41.39
Adjusted EPS (Rs) 4.79 5.89 4.01 3.87 1.71

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 2309.93 3134.98 3238.44 3931.2 3755.09
Total Expenditure 1815.79 2273.61 2594.4 3095.91 2953.73
Operating Profit 494.14 861.37 644.04 835.29 801.36
Other Income 26.46 13.72 18.12 12.88 5.78
Interest 26.86 23.77 16.35 38.67 72
Depreciation 101.82 118.45 126.16 145.56 143.85
Exceptional Items 161.12 0 0 0 0
Profit Before Tax 553.03 732.87 519.65 663.94 591.29
Tax 108.96 180.09 133.13 165.16 155.37
Net Profit 444.07 552.78 386.52 498.79 435.92
Adjusted EPS (Rs.) 17.47 22.32 15.58 20.61 17.99

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 25.42 24.77 24.8 24.2 24.24
Total Reserves 1786.16 2137.85 2505.86 2675.26 3086.71
Borrowings 420.92 333.81 233.7 148.64 50.01
Other N/C liabilities 66.22 58.07 66.66 61.4 76.12
Current liabilities 847.45 1128.33 1541.6 1593.77 1768.55
Total Liabilities 3146.18 3682.83 4372.62 4503.27 5005.63
Assets
Net Block 926.88 985 1170.83 1329.8 1323.67
Capital WIP 100.86 146.58 194.15 63.46 52.53
Intangible WIP 28.92 17.43 16.38 0 0.41
Investments 445.39 591.53 596.53 676.53 941.4
Loans & Advances 169.24 64.42 64.08 115.52 53.7
Other N/C Assets 109.85 0 0 0 0
Current Assets 1365.03 1877.87 2330.65 2317.97 2633.92
Total Assets 3146.18 3682.83 4372.62 4503.27 5005.63
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 553.03 732.87 519.65 663.94 591.29
Adjustment -53.91 153.72 137.11 178.19 229.36
Changes in Assets & Liabilities 115.3 -325.99 -233.77 -1.31 -346.65
Tax Paid -119.63 -185.94 -142.7 -177.14 -157.07
Operating Cash Flow 494.79 374.66 280.29 663.68 316.93
Investing Cash Flow -164.6 -232.74 -317.51 -96.71 -301.74
Financing Cash Flow -212.29 -296.21 151.43 -519.47 26.14
Net Cash Flow 117.9 -154.29 114.21 47.5 41.33

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 41.96 41.96 41.96 38.87 38.87
chigurupati uma devi 3.81 3.81 3.81 3.81 3.81
chigurupati priyanka 0.75 0.75 0.75 0.75 0.75
krishna prasad chigurupat... 34.78 34.78 34.78 31.69 31.69
nikhila reddy yedaguri 0.01 0.01 0.01 0.01 0.01
pragnya chigurupati 0.76 0.76 0.76 0.76 0.76
santhi sree ramanavarapu 0.35 0.35 0.35 0.35 0.35
suseela devi chigurupati 0.03 0.03 0.03 0.03 0.03
tyche investments private... 1.47 1.47 1.47 1.47 1.47
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 58.04 58.04 58.04 61.13 61.13
ab sicav i - internationa... - - 1.05 1.08 1.23
aditya birla sun life tru... 1.27 1.23 1.25 1.09 1.05
axis mutual fund trustee ... - - - 2.62 2.79
basava sankararao kolli 1.21 - 1.20 - 1.20
fidelity funds - india fo... 2.61 2.61 2.61 2.65 1.83
investor education and pr... 0.13 0.13 - 0.13 0.13
life insurance corporatio... 2.30 2.58 2.94 3.49 4.26
schroder international se... - - 1.46 1.46 1.46
akash bhanshali - 1.10 1.10 1.10 -
basava sankara rao kolli - 1.21 - 1.20 -
fidelity funds - asian sm... 3.02 2.34 1.51 1.34 -
government pension fund g... 1.15 1.15 1.15 1.15 -
mahima stocks private lim... 1.13 1.13 1.13 1.13 -
quant mutual fund - quant... - - - 2.20 -
investor education and pr... - - 0.13 - -
quant mutual fund - quant... - - 2.20 - -
quant mutual fund-quant e... - 2.20 - - -
fidelity asian values plc... 1.09 - - - -
ntasain discovery master ... 1.24 - - - -

Ratings & Research Reports

Company Presentations

Company News

Granules India receives Golden Peacock Award for sustainability 14 Nov, 4:55 PM Granules India informs about transcript of conference call 13 Nov, 1:13 PM Granules India informs about analyst meet 7 Nov, 3:37 PM Granules India - Quaterly Results 6 Nov, 1:09 PM Granules India - Quaterly Results 6 Nov, 1:09 PM Granules India - Quaterly Results 6 Nov, 1:09 PM Granules India secures ANDA approval for Bupropion Hydrochloride Extended-Release Tablets 18 Oct, 2:59 PM Granules India unveils mobile cancer screening unit at AIG Hospitals 24 Sep, 2:39 PM USFDA completes inspection at Granules India’s Hyderabad facility 9 Sep, 10:23 AM Granules India gets USFDA’s approval for Glycopyrrolate Oral Solution 20 Aug, 3:27 PM Granules India informs about press release 9 Aug, 6:27 PM Granules India secures ANDA approval for Trazodone Tablets 9 Aug, 12:35 PM Granules India - Quaterly Results 30 Jul, 12:23 PM Granules India - Quaterly Results 30 Jul, 12:23 PM Granules India - Quaterly Results 30 Jul, 12:23 PM Granules India informs about AGM 16 Jul, 4:17 PM Granules India informs about disclosure 11 Jul, 4:43 PM Granules India reports 8% rise in Q4 consolidated net profit 15 May, 3:16 PM Granules India informs about outcome of board meeting 15 May, 3:01 PM Granules India informs about audited financial results 15 May, 2:59 PM Granules India - Quaterly Results 15 May, 12:33 PM Granules India - Quaterly Results 15 May, 12:33 PM Granules India - Quaterly Results 15 May, 12:33 PM Granules India informs about press release 30 Apr, 12:36 PM Granules India’s arm gets USFDA’s approval for Colchicine Capsules 30 Apr, 10:50 AM Granules India gets zero observations from USFDA for Unit V facility in Andhra Pradesh 13 Apr, 1:03 PM Granules India informs about update on GPI facility 3 Apr, 5:01 PM Granules India’s arm gets VAI classification from USFDA for USA Facility 3 Apr, 2:11 PM Granules India informs about closure of trading window 28 Mar, 5:09 PM Granules India informs about clarification 23 Mar, 3:35 PM Granules India informs about appointment of CHRO 11 Mar, 5:00 PM Granules India informs about appointment of additional director 19 Feb, 11:48 AM Granules India - Quaterly Results 23 Jan, 12:20 PM Granules India - Quaterly Results 23 Jan, 12:20 PM Granules India - Quaterly Results 23 Jan, 12:20 PM Granules India informs about disclosure 16 Dec, 10:36 AM Granules India informs about press release 13 Dec, 12:53 PM Granules India gets USFDA’s approval for Pantoprazole Sodium Delayed-Release Tablets 13 Dec, 12:10 PM Granules India’s arm gets USFDA’s approval for Sildenafil for Oral Suspension 4 Dec, 9:58 AM Granules India informs about disclosure 23 Nov, 5:02 PM Granules India informs about analyst meet 16 Nov, 5:06 PM Granules India - Quaterly Results 9 Nov, 1:11 PM Granules India - Quaterly Results 9 Nov, 1:11 PM Granules India - Quaterly Results 9 Nov, 1:11 PM Granules India gets USFDA’s approval for Esomeprazole Magnesium Delayed-Release Capsules 19 Oct, 12:38 PM Granules India informs about press release 19 Oct, 12:32 PM Granules India informs about allotment of equity shares under ESOS 29 Sep, 4:44 PM Granules India receives Accreditation Certificate of Foreign Drug Manufacturer from PMDA 25 Aug, 12:39 PM Granules India gets nod from Brazilian Health Regulatory Agency 25 Aug, 9:22 AM Granules India informs about audio recording of conference call 10 Aug, 9:42 AM

Granules India Stock Price Analysis and Quick Research Report. Is Granules India an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Granules India and its performance over the period of time. Granules India stock price today is Rs 533.9.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Granules India cash from the operating activity was Rs 316.929 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Granules India has a Debt to Equity ratio of 0.3404 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Granules India , the EPS growth was -12.723 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Granules India has OPM of 21.3406279634768 % which is a good sign for profitability.
     
  • ROE: Granules India have a average ROE of 15.0751 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Granules India is Rs 533.9. One can use valuation calculators of ticker to know if Granules India share price is undervalued or overvalued.
Last Updated on:
Brief about Granules India

Granules India Ltd. Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis

Granules India Ltd. is a renowned pharmaceutical company that manufactures and exports active pharmaceutical ingredients (APIs), intermediates, and finished dosages to several global markets. In this stock analysis page, we provide a comprehensive evaluation of Granules India Ltd.'s financial performance, growth potential, and other critical factors that affect its stock. Long-term stock investors looking for stock analysis can use this information to identify potential investment opportunities.

Granules India Ltd. Share Price:

Granules India Ltd.'s share price is a critical metric in evaluating its potential as a long-term stock investment opportunity. Our pre-built screening tools allow investors to track trends in the company's share price over time. Moreover, on our stock analysis page, we provide real-time information on the company's stock price, allowing investors to stay informed and make informed decisions based on current market conditions. A stock's share price is determined by a range of factors such as market sentiment, financial performance, and general economic conditions.

Granules India Ltd. Balance Sheet:

Granules India Ltd.'s balance sheet is essential in determining its financial stability and overall health as a long-term investment option. Analyzing the company's balance sheet enables investors to evaluate the strength of its financial health. By providing access to the company's balance sheet as a downloadable document, our website allows investors to evaluate its assets, liabilities, shareholders' equity, and other critical financial metrics. Our pre-built screening tools offer insights into the company's financial health, including its liquidity, debt levels, and other relevant ratios, making it easier to evaluate its growth potential.

Granules India Ltd. Annual Report:

Granules India Ltd.'s annual report offers valuable insights into the company's strategic initiatives, future goals, and financial performance over the fiscal year. Our website provides investors access to the annual report as a downloadable document, enabling them to evaluate the company's operations and potential for growth. Additionally, our pre-built screening tools offer insights into the company's financial health, allowing investors to analyze its long-term growth potential. Investors can gain deeper insights into the company's performance with our premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, enabling them to make informed investment decisions.

Granules India Ltd. Dividend:

Granules India Ltd.'s dividend payout policy plays a significant role in determining its growth potential over the long term. We provide investors with access to the company's dividend payout history, enabling them to analyze its performance. Our pre-built screening tools can help investors analyze Granules India Ltd.'s dividend payout trends, allowing them to make informed decisions regarding the company's growth potential.

Granules India Ltd. Quarterly Result:

Analyzing Granules India Ltd.'s quarterly results offers crucial insights into its financial performance, including revenue, profit & loss, and other critical financial metrics. Our website provides investors with access to these results as downloadable documents, enabling them to conduct an in-depth analysis of the company's performance. Our pre-built screening tools provide insights into the company's financial growth potential, helping investors make informed investment decisions.

Granules India Ltd. Stock Price:

Granules India Ltd.'s stock price performance is a crucial factor in evaluating its performance as a long-term investment option. Our stock analysis page provides real-time information on the company's stock price, enabling investors to track trends and identify potential investment opportunities. Additionally, our pre-built screening tools can help investors compare Granules India Ltd.'s stock price performance with that of its industry competitors, making it easier to evaluate its growth potential. Our website provides pre-built screening tools to help investors analyze stock price and performance.

Granules India Ltd. Price Chart:

Visual representations of Granules India Ltd.'s share price trends over time can be valuable tools for long-term investors. Price charts enable investors to analyze the company's share price performance, identify trends, and determine potential investment opportunities. Our website provides access to Granules India Ltd.'s price chart, allowing investors to conduct an in-depth analysis of the company's performance. Our pre-built screening tools also enable investors to evaluate trends and compare the company's share price performance with that of industry competitors.

Granules India Ltd. News:

Staying up-to-date with the latest news and developments related to Granules India Ltd. is critical for long-term investors. Our website provides timely news articles about the company, offering updated insights into its financial performance and other critical information that may impact its growth potential. Our pre-built screening tool can also help investors track both local and global news, making it easier to analyze its market performance.

Granules India Ltd. Concall Transcripts:

Granules India Ltd.'s concall transcripts provide investors with valuable insights into the company's future guidance, including its strategic initiatives and financial performance. Our website provides access to these transcripts, enabling long-term investors to stay informed about the company's financial health. Our pre-built screening tools can help investors analyze the information provided in the transcripts, making it easier to make informed decisions about investing in the company's stock.

Granules India Ltd. Investor Presentations:

Analyzing Granules India Ltd.'s investor presentations is crucial in evaluating its potential as a long-term investment option. Our website provides access to these presentations as downloadable documents, enabling investors to analyze them in-depth. Our premium feature tools, such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, can assist investors in analyzing the company's performance and making informed investment decisions.

Granules India Ltd. Promoters and Shareholders:

Analyzing Granules India Ltd.'s promoters and shareholders is essential in evaluating its potential as a long-term investment option. Our stock analysis page provides information about the company's promoters and other shareholders, enabling investors to make informed decisions about their investments. Our pre-built screening tools also enable investors to analyze the company's shareholding patterns, providing valuable insights into its growth potential.

Read More
X